Intercepting Cancer When DNA Surveillance Fails

Episode Summary

Executive Summary: This episode explains how Newscom is leveraging shared frameshift neoantigens in microsatellite instability (MSI) and mismatch repair–deficient cancers to build off-the-shelf and personalized cancer vaccines. CEO Marina Udier argues that broad, viral-vector-based vaccines can enable cancer interception—especially for Lynch syndrome carriers—by priming durable T-cell responses before tumors form, and that biomarker testing plus strategic combinations with checkpoint inhibitors could expand prevention and treatment.

Main Topics: MSI, mismatch repair failure, and frameshift neoantigens (Priority: 5/5): The conversation opens with a plain-language explanation of MSI and DNA mismatch repair, showing how repair failure leads to insertions/deletions, frameshift peptides, and tumor-specific targets that the immune system can recognize. Why vaccine-based cancer interception matters for Lynch syndrome (Priority: 5/5): Udier frames Lynch syndrome as a high-risk inherited condition where current care is surveillance and sometimes prophylactic surgery, while vaccines may allow true biological prevention or interception before cancer develops. Newscom’s platform: viral vectors, payload breadth, and patient selection (Priority: 5/5): The company says its approach combines an optimized viral-vector platform, a broad neoantigen payload, and the right disease setting/patient population to overcome the failures of earlier cancer vaccines. Off-the-shelf versus personalized vaccines (Priority: 4/5): Newscom uses the same vector platform for both programs, changing only the antigen payload. Shared MSI-derived neoantigens support a universal product, while sequencing-based personalization can address individual tumors. Combination therapy and immune escape (Priority: 4/5): Udier argues that broad targeting helps reduce tumor escape and that combining the vaccine with checkpoint inhibitors like PD-1 is especially useful in metastatic disease, while monotherapy may work better in interception settings. Clinical data, safety, and biomarker adoption (Priority: 5/5): She highlights favorable safety, strong immune responses across nearly 200 patients, and early clinical signals in metastatic disease and Lynch carriers, while noting that MSI testing is adopted but Lynch genetic testing remains uneven. Financing, development milestones, and partnerships (Priority: 3/5): The discussion closes on Newscom’s Series C funding, the importance of clinical validation for investor appetite, and the need for future big-pharma partnerships as programs move into later-stage development.

Key Arguments: MSI and mismatch repair deficiency create predictable tumor-specific frameshift peptides that are absent from healthy tissue, making them highly immunogenic targets. A cancer vaccine is more likely to work when it delivers a broad antigen payload, because broader coverage reduces the chance of immune escape. Earlier cancer vaccines often failed because they targeted metastatic disease too late, used less specific tumor-associated antigens, or lacked sufficiently potent platform design. Newscom’s viral-vector prime-boost strategy is intended to generate strong CD8 T-cell responses and durable immune memory. Off-the-shelf vaccines are feasible for MSI because many patients share a common set of frameshift neoantigens; personalized vaccines use the same platform but individualized tumor sequencing data. Checkpoint inhibitors and vaccines are complementary: checkpoint blockade removes immune brakes, while the vaccine initiates new T-cell responses. Cancer interception is positioned as a shift from treating symptomatic cancer to preventing or stopping cancer at the cellular stage in high-risk people. In Lynch syndrome, the biggest unmet need is not detection alone but biological prevention, since surveillance and prophylactic surgery are burdensome and do not stop cancer formation at the root. Clinical and translational data support both safety and immune activity, with observed T-cell infiltration into tumors and durable responses in some metastatic patients. Improved MSI testing has already increased because of checkpoint therapy, and a successful Lynch-directed vaccine could also improve uptake of Lynch genetic testing. Investor interest now depends heavily on clinical data, capital efficiency, and a clear regulatory path; Newscom believes it has those advantages because it already generated human data.

Data Points: Frameshift neoantigens in lead asset: 209 - NUS-209 is described as an off-the-shelf vaccine built around 209 shared frameshift neoantigens. Patients studied: nearly 200 - Udier says consistent immune responses were seen across different trials in nearly 200 patients. Lynch syndrome cancer risk: up to 80% - She cites a very high lifetime cancer risk for Lynch syndrome carriers. Duration of vaccine-specific T-cell responses: 6 to 12 months - Personalized vaccine trials showed broad and durable responses lasting this long in many patients. Series C financing: on the order of $140 million - Newscom’s cumulative fundraising and Series C proceeds were referenced as enabling clinical and translational work. Checkpoint inhibitor label for MSI tumors: 2017 - Pembrolizumab received the first tumor-agnostic label for MSI tumors in the U.S. in 2017. MSI testing increase: 3 to 5-fold - She said MSI testing in metastatic colorectal and endometrial cancers rose after checkpoint inhibitor launches. Trial response duration example: more than 1.5 years - A metastatic MSI-high colorectal patient remained on combination therapy for over a year and a half. Cancer-free screening cadence: annual - Lynch syndrome management was described as involving frequent annual colonoscopies and other tests.

Pivotal Quotes: "What I always believed in and we believed in at NUSCOM is that the quantity matters as well." — Marina Udier: On why broad antigen coverage is important alongside neoantigen quality. "Instead of treating disease when it happens... the idea here is that you would stop cancer at its earlier stages." — Marina Udier: Defining cancer interception as a preventive strategy for high-risk patients. "Your process is your product." — Marina Udier: On how Newscom learned from personalized vaccine development and is automating manufacturing to lower costs.

Implications: If validated in larger studies, MSI/Lynch vaccines could shift oncology from surveillance and late treatment toward prevention, expand biomarker-driven testing, and create a new market for off-the-shelf immunoprevention and combination immunotherapy.